Please assess the completion status of the following clinical trial:

Trial Title: Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed low-grade B-lymphocyte non-Hodgkins lymphoma~* Life expectancy \> 12 months~Exclusion Criteria:~* No known history of HIV infection~* No other active infection~* No peripheral neuropathy ≥ grade 2 within the past 14 days~* No uncontrolled hypertension~* None of the following cardiac conditions:~  * Myocardial infarction within the past 6 months~ * No heart failure~ * Uncontrolled angina~ * Severe uncontrolled ventricular arrhythmias~ * Electrocardiographic evidence of acute ischemia~ * Active conduction system abnormalities~* No serious medical or psychiatric illness that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No prior therapy for non-Hodgkins lymphoma~* No prior bortezomib or rituximab~* At least 3 weeks since prior chemotherapy, radiation therapy, immunotherapy, systemic anticancer biologic therapy, or anticancer hormonal therapy~* At least 2 weeks since prior investigational drugs~* No other concurrent systemic cytotoxic chemotherapy or investigational agents + No leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib and Rituximab (Type: EXPERIMENTAL): On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).